Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1413-1423

  Suen, J Y ^a   Barry, G D ^a   Lohman, R J ^a   Halili, M A ^a   Cotterell, A J ^a   Le, G T ^a   Fairlie, D P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

agonist; antagonist; anti inflammatory; proteinase activated receptor 2

Indexed keywords

CALCIUM ION; ENZYME INHIBITOR; GB 110; GB 88; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PAW EDEMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCIUM; CELL LINE; DIPEPTIDES; EDEMA; HT29 CELLS; HUMANS; INFLAMMATION; ISOXAZOLES; OLIGOPEPTIDES; PEPTIDES; PIPERIDINES; RATS; RECEPTOR, PAR-1; RECEPTOR, PAR-2; SPIRO COMPOUNDS; TRYPSIN;

EID: 84857085346     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01610.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al,. (2007). Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach. J Gastroenterol Hepatol 22: 943-948.
3. Barry GD, Le GT, Fairlie DP, (2006). Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 13: 243-265.
4. Barry GD, Suen JY, Low HB, Pfeiffer B, Flanagan B, Halili M, et al,. (2007). A refined agonist pharmacophore for protease activated receptor 2. Bioorg Med Chem Lett 17: 5552-5557.
5. Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP, (2010). Novel agonists and antagonists for human protease activated receptor 2. J Med Chem 53: 7428-7440.
6. Blakeney JS, Reid RC, Le GT, Fairlie DP, (2007). Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev 107: 2960-3041.
7. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al,. (1996). Molecular cloning, expression and potential functions of the human proteinase-activated receptor 2. Biochem J 314: 1009-1016.
8. Charlton SJ, Vauquelin G, (2010). Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol 161: 1250-1265.
9. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, et al,. (1999). A protective role for protease-activated receptors in the airways. Nature 398: 156-160.
10. Cottrell GS, Amadesi S, Pikios S, Camerer E, Willardsen JA, Murphy BR, et al,. (2007). Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology 132: 2422-2437.
11. Coughlin SR, Camerer E, (2003). PARticipation in inflammation. J Clin Invest 111: 25-27.
12. D'Agostino B, Roviezzo F, De Palma R, Terracciano S, De Nardo M, Gallelli L, et al,. (2007). Activation of protease-activated receptor-2 reduces airways inflammation in experimental allergic asthma. Clin Exp Allergy 37: 1436-1443.
13. Darmoul D, Gratio V, Devaud H, Laburthe M, (2004). Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 279: 20927-20934.
14. Feistritzer C, Lenta R, Riewald M, (2005). Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 3: 2798-2805.
15. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, et al,. (2003). Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 111: 35-41.
16. Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, Baruch A, et al,. (2005). A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci USA 102: 8363-8368.
17. Hirota M, Ohmuraya M, Baba H, (2006). The role of trypsin, trypsin inhibitor, and trypsin receptor in the onset and aggravation of pancreatitis. J Gastroenterol 41: 832-836.
18. Hollenberg MD, Saifeddine M, al-Ani B, (1996). Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. Mol Pharmacol 49: 229-233.
19. Iwaki K, Shibata K, Ohta M, Endo Y, Uchida H, Tominaga M, et al,. (2008). A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model. Int J Cancer 122: 658-663.
20. Kajikawa H, Yoshida N, Katada K, Hirayama F, Handa O, Kokura S, et al,. (2007). Helicobacter pylori activates gastric epithelial cells to produce interleukin-8 via protease-activated receptor 2. Digestion 76: 248-255.
21. Kanke T, Ishiwata H, Kabeya M, Saka M, Doli T, Hattori Y, et al,. (2005). Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. Br J Pharmacol 145: 255-263.
22. Kanke T, Kabeya M, Kubo S, Kondo S, Yasuoka K, Tagashira J, et al,. (2009). Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol 158: 361-371.
23. Kawabata A, Kanke T, Yonezawa D, Ishiki T, Saka M, Kabeya M, et al,. (2004). Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo. J Pharmacol Exp Ther 309: 1098-1107.
24. Kawabata A, Matsunami M, Sekiquchi F, (2008). Gastrointestinal roles for proteinase-activated receptors in health and disease. Br J Pharmacol 153 (Suppl. 1): S230-S240.
25. Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD, et al,. (2006). Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 316: 1017-1024.
26. Kelso EB, Ferrell WR, Lockhart JC, Elias-Jones I, Hembrough T, Dunning L, et al,. (2007). Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium. Arthritis Rheum 56: 765-771.
27. Kenakin T, (1997). Competitive antagonism. In:, McLaughlin MA, (ed.). Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven Publishers: Philadelphia, PA, pp. 369-371.
28. Kenakin T, Jenkinson S, Watson C, (2006). Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723.
29. Kumar P, Lau CS, Mathur M, Wang P, DeFea KA, (2007). Differential effects of beta-arrestins on the internalization, desensitization and ERK1/2 activation downstream of protease activated receptor-2. Am J Physiol Cell Physiol 293: C346-C357.
30. Lam FF, (2007). Role of protease-activated receptor 2 in joint inflammation. Arthritis Rheum 56: 3514-3517.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23: 3-25.
32. MacFarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R, (2001). Proteinase-activated receptors. Pharmacol Rev 53: 245-282.
33. Maeda K, Hirota M, Kimura Y, Ichihara A, Ohmuraya M, Sugita H, et al,. (2005). Proinflammatory role of trypsin and protease-activated receptor-2 in a rat model of acute pancreatitis. Pancreas 31: 54-62.
34. Matej R, Mandakova P, Netikova I, Pouckova P, Olejar T, (2007). Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDA MB-231. Physiol Res 56: 475-484.
35. McIntosh KA, Plevin R, Ferrell WR, Lockhart JC, (2007). The therapeutic potential of proteinase-activated receptors in arthritis. Curr Opin Pharmacol 7: 334-338.
36. Miyata S, Koshikawa N, Yasumitsu H, Miyazaki K, (2000). Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem 275: 4592-4598.
37. Moriyuki K, Sekiguchi F, Matsubara K, Nishikawa H, Kawabata A, (2009). Proteinase-activated receptor-2-triggered prostaglandin E(2) release, but not cyclooxygenase-2 upregulation, requires activation of the phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB pathway in human alveolar epithelial cells. J Pharmacol Sci 111: 269-275.
38. Moussa L, Apostolopoulos J, Davenport P, Tchonque J, Tipping PG, (2007). Protease-activated receptor-2 augments experimental crescentic glomerulonephritis. Am J Pathol 171: 800-808.
39. Nishibori M, Mori S, Takahashi HK, (2005). Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. J Pharmacol Sci 97: 25-30.
40. Niu QX, Chen HQ, Chen ZY, Fu YL, Lin JL, He SH, (2008). Induction of inflammatory cytokine release from human umbilical vein endothelial cells by agonists of proteinase-activated receptor-2. Clin Exp Pharmacol Physiol 35: 89-96.
41. Ricks TK, Trejo J, (2009). Phosphorylation of protease-activated receptor-2 differentially regulates desensitization and internalization. J Biol Chem 284: 34444-34457.
42. Ryden L, Grabau D, Schaffner F, Jonsson PE, Ruf W, Belting M, (2010). Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 126: 2330-2340.
43. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, et al,. (2004). A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 24: 1401-1406.
44. Shin K, Nigrovic PA, Crish J, Boilard E, McNeil HP, Larabee KS, et al,. (2009). Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 182: 647-656.
45. Stalheim L, Ding Y, Gullapalli A, Paing MM, Wolfe BL, Morris DR, et al,. (2005). Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking. Mol Pharmacol 67: 78-87.
46. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al,. (2005). Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26: 1-43.
47. Suen JY, Gardiner B, Grimmond S, Fairlie DP, (2010). Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS ONE 5: e13809.
48. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD, (2002). Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
49. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace J, (1999). Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127: 1083-1090.
50. Vesey DA, Hooper JD, Gobe GC, Johnson DW, (2007a). Potential physiological and pathophysiological roles for protease-activated receptor-2 in the kidney. Nephrology 12: 36-43.
51. Vesey DA, Kruger WA, Poronnik P, Gobe GC, Johnson DW, (2007b). Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation. Am J Physiol Renal Physiol 293: F1441-F1449.